IBRX271119C00020000
IBRX Nov 19 2027 20.00 Call
optionOPRA
EODOct 15, 2026
1.76USD+9.317%(+0.15)1Vol795OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
20
Expiration
Nov 19, 2027
DTE
395d
Moneyness
OTM
Intrinsic
$0.00
IBRX 20 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | — | — | 0 | 0 |
| Oct 30, 2026 | 10d | — | — | 0 | 0 |
| Nov 6, 2026 | 17d | — | — | 0 | 0 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 20, 2026 | 31d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $0.29 | -25.64% | 38 | 10,172 |
| Mar 19, 2027 | 150d | $0.50 | -26.47% | 40 | 61 |
| Apr 16, 2027 | 178d | — | — | 0 | 0 |
| May 21, 2027 | 213d | — | — | 0 | 0 |
| Aug 20, 2027 | 304d | — | — | 0 | 0 |
| Nov 19, 2027 | 395d | $1.76 | +9.32% | 1 | 795 |
| Jan 21, 2028 | 458d | $1.50 | -23.08% | 46 | 1,671 |
| Mar 17, 2028 | 514d | — | — | 0 | 0 |
| Jan 19, 2029 | 822d | $2.75 | -14.06% | 32 | 559 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.